Platelet activation in bypass surgery for critical limb ischemia

Vascular and Endovascular Surgery

Volumn 41, Issue 4, 2007, Pages 322-329

  Mohan, Irwin V ^a,d   Mikhailidis, Dimitri P ^b   Stansby, Gerard P ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Aggregation; Femoro popliteal bypass; Peripheral arterial disease; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; WARFARIN;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BYPASS SURGERY; CONTROLLED STUDY; DISSECTION; FEMALE; FEMOROPOPLITEAL BYPASS; FLOW CYTOMETRY; GRAFT OCCLUSION; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; RANK SUM TEST; STATISTICAL ANALYSIS; SURGICAL APPROACH; SURGICAL TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TURBIDIMETRY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CRITICAL ILLNESS; FEMALE; FEMORAL ARTERY; FLOW CYTOMETRY; HUMANS; ISCHEMIA; LEG; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; POPLITEAL ARTERY; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 34547871988     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574407302753     Document Type: Article

References (32)

1. Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost. 2004 ; 10: 9-18.
2. Collins TC, Souchek J., Beyth RJ Benefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. Am J Med. 2004 ; 117: 93-99.
3. Barradas MA, Stansby G., Hamilton G., Mikhailidis DP Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol. 1994 ; 13: 202-207.
4. Walters TK, Mitchell DC, Wood RF Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg. 1993 ; 80: 1266-1268.
5. Trifiletti A., Barbera N., Pizzoleo MA, et al. Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. J Cardiovasc Surg (Torino). 1995 ; 36: 483-485.
6. Sixma JJ Interaction of blood platelets with the vessel wall. In: Bloom AL, Forbes CD, Thomas DF, Tuddenham EGD, eds. Haemostasis and Thrombosis. 3 rd ed. Edinburgh: Churchill Livingstone; 1994: 259-285.
7. Cheshire Njw, Wolfe Jhn, Barradas MA, Chambler AW, Mikhailidis DP Smoking and plasma fibrinogen, lipoprotein (a), and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg. 1996 ; 11: 479-486.
8. Robless PA, Okonko D., Lintott P., Mansfield AO, Mikhailidis DP, Stansby GP Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003 ; 25: 16-22.
9. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 ; 93: 11877-11882.
10. McBane RD II, Karnicki K., Tahirkheli N., Miller RS, Owen WG The impact of peripheral arterial disease on circulating platelets. Thromb Res. 2004 ; 113: 137-145.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994 ; 308: 81-106.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86.
13. Jagroop IA, Matsagas MI, Geroulakos G., Mikhailidis DP The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 2004 ; 15: 117-125.
14. Dutch Boa Trial Participants. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet. 2000 ; 355: 346-351.
15. Michelson AD, Furman MI Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999 ; 6: 342-348.
16. Abrams C., Shattil SJ Immunological detection of activated platelets in clinical disorders. Thromb and Haemost. 1991 ; 65: 467-473.
17. Barradas MA, O'Donoghue S., Jagroop A., Mikhailidid DP Laboratory techniques in drug development (2): advantages of whole blood platelet aggregation measured by a cell counter (Coulter T-890) in drug evaluation. J Drug Dev. 1992 ; 5: 155-166.
18. Tsakiris DA, Tschopl M., Wolf F., et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis. 2000 ; 11: 165-173.
19. McBane RD II, Karnicki K., Tahirkheli N., Miller RS, Owen WG Platelet characteristics associated with coronary artery disease. J Thromb Haemost. 2003 ; 1: 1296-1303.
20. Labios M., Martinez M., Gabriel F., Guiral V., Martinez E., Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res. 2005 ; 115: 263-270.
21. Holme PA, Orvim U., Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997 ; 17: 646-653.
22. Fuster V., Badimon L., Badimon JJ, Chesebro JH The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992 ; 326: 242-250.
23. Sakariassen KS, Örning L., Stormorken H. Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets. 1997 ; 8: 385-390.
24. Robless P., Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001 ; 88: 787-800.
25. Schneider DJ, Tracy PB, Mann KG, Sobel BE Differential effects of anticoagulants on the activation of platelets ex-vivo. Circulation. 1997 ; 96: 2877-2883.
26. Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L., Wakeling A., Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest. 1985 ; 15: 313-319.
27. Legrand C., Morandi V., Mendelovitz S., Shaken H., Hartman JR, Panet A. Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin. Arterioscler Thromb. 1994 ; 14: 1784-1791.
28. Viscentin GP, Ford SE, Scott JP, Aster RH Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994 ; 93: 81-88.
29. Schroder K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1992 ; 4: 252-261.
30. Mastagas M., Jagroop IA, Geroulakos G., Mikhailidis DP The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost. 2003 ; 9: 115-120.
31. , Joseph JE, Machin SJ New antiplatelet drugs. Blood Rev. 1997 ; 11: 178-190.
32. Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol. 2005 ; 17: 427-432.